Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Овариальный эндометриоз и проблема сохранения фертильности
Овариальный эндометриоз и проблема сохранения фертильности
Чернуха Г.Е., Думановская М.Р., Ильина Л.М. Овариальный эндометриоз и проблема сохранения фертильности. Гинекология. 2021; 23 (2): 110–116. DOI: 10.26442/20795696.2021.2.200822
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Цель. Провести обзор последних публикаций, касающихся современного ведения женщин с овариальным эндометриозом, не заинтересованных в беременности на данный момент времени, но желающих сохранить фертильность на будущее.
Материалы и методы. Проведен анализ публикаций последних лет по заданной теме.
Результаты. Овариальный эндометриоз связан с бесплодием по ряду причин, включая гонадотоксический эффект и снижение овариального резерва после хирургического лечения. Медикаментозное лечение может быть терапией первого выбора для пациенток с эндометриозом яичников и тазовой болью, которым незамедлительно не нужна беременность и нет экстренных причин для хирургического лечения, для предупреждения прогрессирования заболевания. Долговременная медикаментозная терапия после операции эффективна для профилактики рецидива эндометриомы, повторного хирургического лечения, дополнительного снижения овариального резерва и сохранения фертильности на будущее.
Заключение. Ведение овариального эндометриоза должно быть персонализированным согласно намерениям и приоритетам пациентки. Долговременная терапия прогестинами является наиболее подходящим лечением для сохранения фертильности у женщин до применения хирургического лечения или вспомогательных репродуктивных технологий при необходимости.
Ключевые слова: эндометриоз, овариальный эндометриоз, фертильность, хирургическое лечение, гормональное лечение, вспомогательные репродуктивные технологии
Materials and methods. The analysis of latest publications on this topic has been carried out.
Results. Ovarian endometriosis is associated with infertility due to several factors including potential gonadotoxic effect per se and ovarian reserve decline after surgical treatment. Medical treatment is the first-line therapeutic option for patients with pelvic pain and no desire for immediate pregnancy in absence indications for the urgent surgery, for prevention disease progression. Postoperative long-term medical therapy has been effective in the prevention of endometrioma recurrence, repeated surgery, additional ovarian reserve decline and preserve fertility in future.
Conclusion. Ovarian endometriosis management should be individualized according to the patient’s intentions and priorities. Long-term progestins most appropriate therapy for fertility preservation in women prior to performing surgery or provide assisted reproductive technologies, if needed.
Keywords: endometriosis, ovarian endometriosis, fertility, surgery, hormonal treatment, assisted reproductive technologies
Материалы и методы. Проведен анализ публикаций последних лет по заданной теме.
Результаты. Овариальный эндометриоз связан с бесплодием по ряду причин, включая гонадотоксический эффект и снижение овариального резерва после хирургического лечения. Медикаментозное лечение может быть терапией первого выбора для пациенток с эндометриозом яичников и тазовой болью, которым незамедлительно не нужна беременность и нет экстренных причин для хирургического лечения, для предупреждения прогрессирования заболевания. Долговременная медикаментозная терапия после операции эффективна для профилактики рецидива эндометриомы, повторного хирургического лечения, дополнительного снижения овариального резерва и сохранения фертильности на будущее.
Заключение. Ведение овариального эндометриоза должно быть персонализированным согласно намерениям и приоритетам пациентки. Долговременная терапия прогестинами является наиболее подходящим лечением для сохранения фертильности у женщин до применения хирургического лечения или вспомогательных репродуктивных технологий при необходимости.
Ключевые слова: эндометриоз, овариальный эндометриоз, фертильность, хирургическое лечение, гормональное лечение, вспомогательные репродуктивные технологии
________________________________________________
Materials and methods. The analysis of latest publications on this topic has been carried out.
Results. Ovarian endometriosis is associated with infertility due to several factors including potential gonadotoxic effect per se and ovarian reserve decline after surgical treatment. Medical treatment is the first-line therapeutic option for patients with pelvic pain and no desire for immediate pregnancy in absence indications for the urgent surgery, for prevention disease progression. Postoperative long-term medical therapy has been effective in the prevention of endometrioma recurrence, repeated surgery, additional ovarian reserve decline and preserve fertility in future.
Conclusion. Ovarian endometriosis management should be individualized according to the patient’s intentions and priorities. Long-term progestins most appropriate therapy for fertility preservation in women prior to performing surgery or provide assisted reproductive technologies, if needed.
Keywords: endometriosis, ovarian endometriosis, fertility, surgery, hormonal treatment, assisted reproductive technologies
Полный текст
Список литературы
1. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrin. 2019; 15: 666–82.
DOI: 10.1038/s41574-019-0245-z
2. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017; 6 (1): 34–41. DOI: 10.1007/s13669-017-0187-1
3. Ghiasi M, Kulkarni MT, Missmer SA. Is Endometriosis More Common and More Severe Than It Was 30 Years Ago? J Minim Invasive Gynecol. 2020; 27 (2): 452–61. DOI: 10.1016/j.jmig.2019.11.018
4. Матвеева Н.Н., Табачкова О.А. Структура доброкачественных новообразований яичников у женщин репродуктивного возраста. Бюл. мед. интернет-конференций. 2016; 6 (2): 424 [Matveeva NN, Tabachkova OA. Struktura dobrokachestvennykh novoobrazovanii iaichnikov u zhenshchin reproduktivnogo vozrasta. Biul. med. internet-konferentsii. 2016; 6 (2): 424 (in Russian)].
5. Cranney R, Condous G, Reid S. An update on the diagnosis, surgical management, and fertility outcomes for women with endometrioma. Acta Obstet Gynecol Scand. 2017; 96 (6): 633–43. DOI: 10.1111/aogs.13114
6. Alborzi S, Sorouri ZZ, Askari E, et al. The success of various endometrioma treatments in infertility: A systematic review and meta‐analysis of prospective studies. Reprod Med Biol. 2019; 18 (4): 312–22. DOI: 10.1002/rmb2.12286
7. Miller CE. The Endometrioma Treatment Paradigm when Fertility Is Desired: A Systematic Review. J Minim Invasive Gynecol. 2021; 28 (3): 575–86. DOI: 10.1016/j.jmig.2020.11.020
8. Dunselman G, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29 (3): 400–12. DOI: 10.1093/humrep/det457
9. Дублинская Е.Д., Дутов А.А., Лаптева Н.В., и др. Эндометриоидные кисты яичников и фертильность: дискуссионные аспекты. Вопр. гинекологии, акушерства и перинатологии. 2015; 14 (5): 27–35 [Dublinskaia ED, Dutov AA, Lapteva NV, et al. Endometrioidnye kisty iaichnikov i fertil’nost’: diskussionnye aspekty. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (5): 27–35 (in Russian)].
10. Li X, Zhang W, Chao X, et al. Clinical characteristics difference between early and late recurrence of ovarian endometriosis after laparoscopic cystectomy. Arch Gynecol Obstet. 2020; 302: 905–13. DOI: 10.1007/s00404-020-05657-5
11. Seo JW, Lee DY, Yoon BK, et al. The age-related recurrence of endometrioma after conservative surgery. Eur J Obstet Gynecol Reprod Biol. 2017; 208: 81–5. DOI: 10.1016/j.ejogrb.2016.11.015
12. Kitajima M, Defrere S, Dolmans MM, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011; 96: 685–91. DOI: 10.1016/j.fertnstert.2011.06.064
13. Sanchez AM, Vigano P, Somigliana E, et al. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma‐mediated damage to the ovary. Hum Reprod Update. 2014; 20 (2): 217–30. DOI: 10.1093/humupd/dmt053
14. Sanchez AM, Vanni VS, Bartiromo L, et al. Is the oocyte quality affected by endometriosis? A review of the literature. J Ovarian Res. 2017; 10: 43. DOI: 10.1186/s13048-017-0341-4
15. Matsuzaki S, Schubert B. Oxidative stress status in normal ovarian cortex surrounding ovarian endometriosis. Fertil Steril. 2010; 93 (7): 2431–2. DOI: j.fertnstert.2009.08.068
16. Li Y, Li R, Ouyang N, et al. Investigating the impact of local inflammation on granulosa cells and follicular development in women with ovarian endometriosis. Fertil Steril. 2019; 112: 882–91. DOI: 10.1016/j.fertnstert.2019.07.007
17. Yland J, Carvalho LFP, Beste M, et al. Endometrioma, the follicular fluid inflammatory network and its association with oocyte and embryo characteristics. Reprod Biomed Online. 2020; 40 (3): 399–408. DOI: 10.1016/j.rbmo.2019.12.005
18. Muzii L, Di Tucci C, Di Feliciantonio M, et al. Anti-mullerian hormone is reduced in the presence of ovarian endometriomas: a systematic review and meta-analysis. Fertil Steril. 2018; 110: 932–40. DOI: 10.1016/j.fertnstert.2018.06.025
19. Stochino-Loi E, Darwish B, Mircea O, et al. Does preoperative antimüllerian hormone level influence postoperative pregnancy rate in women undergoing surgery for severe endometriosis? Fertil Steril. 2017; 107: 707–13. DOI: 10.1016/j.fertnstert.2016.12.013
20. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum Reprod Update. 2015; 21: 809–25. DOI: 10.1093/humupd/dmv035
21. Benaglia L, Castiglioni M, Paffoni A, et al. Is endometrioma-associated damage to ovarian reserve progressive? Insights from IVF cycles. Eur J Obstet Gynecol Reprod Biol. 2017; 217: 101–5. DOI: 10.1016/j.ejogrb.2017.08.034
22. Kasapoglu I, Ata B, Uyaniklar O, et al. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018; 110: 122–7. DOI: 10.1016/j.fertnstert.2018.03.015
23. Ding D, Wang X, Chen Y, et al. Evidence in Support for the Progressive Nature of Ovarian Endometriomas. J Clin Endocrinol Metab. 2020; 105 (7): dgaa189. DOI: 10.1210/clinem/dgaa189
24. Kusunoki M, Fujiwara Y, Komohara Y, et al. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. Med Mol Morphol. 2021 Jan 4. Online ahead of print. DOI: 10.1007/s00795-020-00272-4
25. Адамян Л.В. Диагностика и лечение доброкачественнных новообразований яичников с позиций профилактики рака. Клинические рекомендации Минздрава России. М., 2018; с. 20–31 [Adamyan LV. Diagnostics and treatment of benign ovarian neoplasms from the standpoint of cancer prevention. Clinical guidelines of the Ministry of Health of Russia. Moscow, 2018; р. 20–31 (in Russian)].
26. Working group of ESGE, ESHRE and WES; Saridogan E, Becker CM, Feki A, et al. Recommendations for the Surgical Treatment of Endometriosis. Part 1: Ovarian Endometrioma. Human Reprod Open 2017; 4. DOI: 10.1093/hropen/hox016
27. Singh SS, Gude K, Perdeaux E, et al. Surgical Outcomes in Patients With Endometriosis: A Systematic Review. J Obstet Gynaecol Can. 2020; 7: 881–8. DOI: 10.1016/j.jogc.2019.08.004
28. Lessey BA, Gordts S, Donnez O, et al. Ovarian endometriosis and infertility: in vitro fertilization (IVF) or surgery as the first approach? Fertil Steril. 2018; 110 (7): 1218–26. DOI: 10.1016/j.fertnstert.2018.10.003
29. Shaltout MF, Elsheikhah A, Maged AM, et al. A randomized controlled trial of a new technique for laparoscopic management of ovarian endometriosis preventing recurrence and keeping ovarian reserve. J Ovarian Res. 2019; 12 (1): 66. DOI: 10.1186/s13048-019-0542-0
30. Nirgianakis K, Ma L, McKinnon B, Mueller MD. Recurrence Patterns after Surgery in Patients with Different Endometriosis Subtypes:
A Long-Term Hospital-Based Cohort Study. J Clin Med. 2020; 9 (2): 496. DOI: 10.3390/jcm9020496
31. Romualdi D, Zannoni GF, Lanzoneet A, et al. Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations. Fertil Steril. 2011; 96: 374–8. DOI: 10.1016/j.fertnstert.2011.05.078
32. Zakhari A, Delpero E, McKeown S, et al. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2021; 27 (1): 96–107. DOI: 10.1093/humupd/dmaa033
33. Vercellini P, De Matteis S, Somigliana E, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2013; 92: 8–16. DOI: 10.1111/j.1600-0412.2012.01470.x
34. Chapron C, Souza C, Borghese B, et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod. 2011; 26 (8): 2028–35. DOI: 10.1093/humrep/der156
35. Kwok H, Jiang H, Li T, et al. Lesion distribution characteristics of deep infiltrating endometriosis with ovarian endometrioma: an observational clinical study. BMC Women’s Health. 2020; 20: 111. DOI: 10.1186/s12905-020-00974-y
36. Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020; 26 (4): 565–85. DOI: 10.1093/humupd/dmaa009
37. Murji A, Biberoğlu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36 (5): 895–907. DOI: 10.1080/03007995.2020.1744120
38. Park SY, Kim SH, Chae HD, et al. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months. Clin Exp Reprod Med. 2016; 43: 215–20. DOI: 10.5653/cerm.2016.43.4.215
39. Adachi K, Takahashi K, Nakamura K, et al. Postoperative Administration of Dienogest for Suppressing Recurrence of Disease and Relieving Pain in Subjects With Ovarian Endometriomas. Gynecol Endocrinol. 2016; 32 (8): 646–9. DOI: 10.3109/09513590.2016.1147547
40. Chandra A, Rho AM, Jeonget K, et al. Clinical Experience of Long-Term Use of Dienogest After Surgery for Ovarian Endometrioma. Obstet Gynecol Sci. 2018; 61 (1): 111–7. DOI: 10.5468/ogs.2018.61.1.111
41. Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020; 36 (1): 84–6. DOI: 10.1080/09513590.2019.1640674
42. Mabrouk M, Paradisi R, Arena A, et al. Short-term histopathological effects of dienogest therapy on ovarian endometriomas: in vivo, nonrandomized, controlled trial. Gynecol Endocrinol. 2018; 34 (5): 399–403. DOI: 10.1080/09513590.2017.1405932
43. Hayashi A, Tanabe A, Kawabe S, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovar Res. 2012; 5: 31–9. DOI: 10.1186/1757-2215-5-31
44. Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020; 36 (1): 81–8. DOI: 10.1080/09513590.2019.1640199
45. Koshiba A, Mori T, Okimura H, et al. Dienogest Therapy During the Early Stages of Recurrence of Endometrioma Might Be an Alternative Therapeutic Option to Avoid Repeat Surgeries. J Obstet Gynaecol Res. 2018; 44 (7): 1189–341. DOI: 10.1111/jog.13725
46. Lee JH, Song JY, Yi KW, et al. Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reprod Sci. 2018; 25 (10): 1515–22. DOI: 10.1177/1933719118779733
47. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017; 211: 108–11. DOI: 10.1016/j.ejogrb.2017.02.015
48. Barra F, Scala C, Maggiore ULR, Ferrero S. Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis. J Clin Med. 2020; 9 (1): 154. DOI: 10.3390/jcm9010154
DOI: 10.1038/s41574-019-0245-z
2. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017; 6 (1): 34–41. DOI: 10.1007/s13669-017-0187-1
3. Ghiasi M, Kulkarni MT, Missmer SA. Is Endometriosis More Common and More Severe Than It Was 30 Years Ago? J Minim Invasive Gynecol. 2020; 27 (2): 452–61. DOI: 10.1016/j.jmig.2019.11.018
4. Matveeva NN, Tabachkova OA. Struktura dobrokachestvennykh novoobrazovanii iaichnikov u zhenshchin reproduktivnogo vozrasta. Biul. med. internet-konferentsii. 2016; 6 (2): 424 (in Russian)
5. Cranney R, Condous G, Reid S. An update on the diagnosis, surgical management, and fertility outcomes for women with endometrioma. Acta Obstet Gynecol Scand. 2017; 96 (6): 633–43. DOI: 10.1111/aogs.13114
6. Alborzi S, Sorouri ZZ, Askari E, et al. The success of various endometrioma treatments in infertility: A systematic review and meta‐analysis of prospective studies. Reprod Med Biol. 2019; 18 (4): 312–22. DOI: 10.1002/rmb2.12286
7. Miller CE. The Endometrioma Treatment Paradigm when Fertility Is Desired: A Systematic Review. J Minim Invasive Gynecol. 2021; 28 (3): 575–86. DOI: 10.1016/j.jmig.2020.11.020
8. Dunselman G, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29 (3): 400–12. DOI: 10.1093/humrep/det457
9. Dublinskaia ED, Dutov AA, Lapteva NV, et al. Endometrioidnye kisty iaichnikov i fertil’nost’: diskussionnye aspekty. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (5): 27–35 (in Russian)
10. Li X, Zhang W, Chao X, et al. Clinical characteristics difference between early and late recurrence of ovarian endometriosis after laparoscopic cystectomy. Arch Gynecol Obstet. 2020; 302: 905–13. DOI: 10.1007/s00404-020-05657-5
11. Seo JW, Lee DY, Yoon BK, et al. The age-related recurrence of endometrioma after conservative surgery. Eur J Obstet Gynecol Reprod Biol. 2017; 208: 81–5. DOI: 10.1016/j.ejogrb.2016.11.015
12. Kitajima M, Defrere S, Dolmans MM, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011; 96: 685–91. DOI: 10.1016/j.fertnstert.2011.06.064
13. Sanchez AM, Vigano P, Somigliana E, et al. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma‐mediated damage to the ovary. Hum Reprod Update. 2014; 20 (2): 217–30. DOI: 10.1093/humupd/dmt053
14. Sanchez AM, Vanni VS, Bartiromo L, et al. Is the oocyte quality affected by endometriosis? A review of the literature. J Ovarian Res. 2017; 10: 43. DOI: 10.1186/s13048-017-0341-4
15. Matsuzaki S, Schubert B. Oxidative stress status in normal ovarian cortex surrounding ovarian endometriosis. Fertil Steril. 2010; 93 (7): 2431–2. DOI: j.fertnstert.2009.08.068
16. Li Y, Li R, Ouyang N, et al. Investigating the impact of local inflammation on granulosa cells and follicular development in women with ovarian endometriosis. Fertil Steril. 2019; 112: 882–91. DOI: 10.1016/j.fertnstert.2019.07.007
17. Yland J, Carvalho LFP, Beste M, et al. Endometrioma, the follicular fluid inflammatory network and its association with oocyte and embryo characteristics. Reprod Biomed Online. 2020; 40 (3): 399–408. DOI: 10.1016/j.rbmo.2019.12.005
18. Muzii L, Di Tucci C, Di Feliciantonio M, et al. Anti-mullerian hormone is reduced in the presence of ovarian endometriomas: a systematic review and meta-analysis. Fertil Steril. 2018; 110: 932–40. DOI: 10.1016/j.fertnstert.2018.06.025
19. Stochino-Loi E, Darwish B, Mircea O, et al. Does preoperative antimüllerian hormone level influence postoperative pregnancy rate in women undergoing surgery for severe endometriosis? Fertil Steril. 2017; 107: 707–13. DOI: 10.1016/j.fertnstert.2016.12.013
20. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum Reprod Update. 2015; 21: 809–25. DOI: 10.1093/humupd/dmv035
21. Benaglia L, Castiglioni M, Paffoni A, et al. Is endometrioma-associated damage to ovarian reserve progressive? Insights from IVF cycles. Eur J Obstet Gynecol Reprod Biol. 2017; 217: 101–5. DOI: 10.1016/j.ejogrb.2017.08.034
22. Kasapoglu I, Ata B, Uyaniklar O, et al. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018; 110: 122–7. DOI: 10.1016/j.fertnstert.2018.03.015
23. Ding D, Wang X, Chen Y, et al. Evidence in Support for the Progressive Nature of Ovarian Endometriomas. J Clin Endocrinol Metab. 2020; 105 (7): dgaa189. DOI: 10.1210/clinem/dgaa189
24. Kusunoki M, Fujiwara Y, Komohara Y, et al. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. Med Mol Morphol. 2021 Jan 4. Online ahead of print. DOI: 10.1007/s00795-020-00272-4
25. Adamyan LV. Diagnostics and treatment of benign ovarian neoplasms from the standpoint of cancer prevention. Clinical guidelines of the Ministry of Health of Russia. Moscow, 2018; р. 20–31 (in Russian)
26. Working group of ESGE, ESHRE and WES; Saridogan E, Becker CM, Feki A, et al. Recommendations for the Surgical Treatment of Endometriosis. Part 1: Ovarian Endometrioma. Human Reprod Open 2017; 4. DOI: 10.1093/hropen/hox016
27. Singh SS, Gude K, Perdeaux E, et al. Surgical Outcomes in Patients With Endometriosis: A Systematic Review. J Obstet Gynaecol Can. 2020; 7: 881–8. DOI: 10.1016/j.jogc.2019.08.004
28. Lessey BA, Gordts S, Donnez O, et al. Ovarian endometriosis and infertility: in vitro fertilization (IVF) or surgery as the first approach? Fertil Steril. 2018; 110 (7): 1218–26. DOI: 10.1016/j.fertnstert.2018.10.003
29. Shaltout MF, Elsheikhah A, Maged AM, et al. A randomized controlled trial of a new technique for laparoscopic management of ovarian endometriosis preventing recurrence and keeping ovarian reserve. J Ovarian Res. 2019; 12 (1): 66. DOI: 10.1186/s13048-019-0542-0
30. Nirgianakis K, Ma L, McKinnon B, Mueller MD. Recurrence Patterns after Surgery in Patients with Different Endometriosis Subtypes:
A Long-Term Hospital-Based Cohort Study. J Clin Med. 2020; 9 (2): 496. DOI: 10.3390/jcm9020496
31. Romualdi D, Zannoni GF, Lanzoneet A, et al. Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations. Fertil Steril. 2011; 96: 374–8. DOI: 10.1016/j.fertnstert.2011.05.078
32. Zakhari A, Delpero E, McKeown S, et al. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2021; 27 (1): 96–107. DOI: 10.1093/humupd/dmaa033
33. Vercellini P, De Matteis S, Somigliana E, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2013; 92: 8–16. DOI: 10.1111/j.1600-0412.2012.01470.x
34. Chapron C, Souza C, Borghese B, et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod. 2011; 26 (8): 2028–35. DOI: 10.1093/humrep/der156
35. Kwok H, Jiang H, Li T, et al. Lesion distribution characteristics of deep infiltrating endometriosis with ovarian endometrioma: an observational clinical study. BMC Women’s Health. 2020; 20: 111. DOI: 10.1186/s12905-020-00974-y
36. Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020; 26 (4): 565–85. DOI: 10.1093/humupd/dmaa009
37. Murji A, Biberoğlu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36 (5): 895–907. DOI: 10.1080/03007995.2020.1744120
38. Park SY, Kim SH, Chae HD, et al. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months. Clin Exp Reprod Med. 2016; 43: 215–20. DOI: 10.5653/cerm.2016.43.4.215
39. Adachi K, Takahashi K, Nakamura K, et al. Postoperative Administration of Dienogest for Suppressing Recurrence of Disease and Relieving Pain in Subjects With Ovarian Endometriomas. Gynecol Endocrinol. 2016; 32 (8): 646–9. DOI: 10.3109/09513590.2016.1147547
40. Chandra A, Rho AM, Jeonget K, et al. Clinical Experience of Long-Term Use of Dienogest After Surgery for Ovarian Endometrioma. Obstet Gynecol Sci. 2018; 61 (1): 111–7. DOI: 10.5468/ogs.2018.61.1.111
41. Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020; 36 (1): 84–6. DOI: 10.1080/09513590.2019.1640674
42. Mabrouk M, Paradisi R, Arena A, et al. Short-term histopathological effects of dienogest therapy on ovarian endometriomas: in vivo, nonrandomized, controlled trial. Gynecol Endocrinol. 2018; 34 (5): 399–403. DOI: 10.1080/09513590.2017.1405932
43. Hayashi A, Tanabe A, Kawabe S, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovar Res. 2012; 5: 31–9. DOI: 10.1186/1757-2215-5-31
44. Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020; 36 (1): 81–8. DOI: 10.1080/09513590.2019.1640199
45. Koshiba A, Mori T, Okimura H, et al. Dienogest Therapy During the Early Stages of Recurrence of Endometrioma Might Be an Alternative Therapeutic Option to Avoid Repeat Surgeries. J Obstet Gynaecol Res. 2018; 44 (7): 1189–341. DOI: 10.1111/jog.13725
46. Lee JH, Song JY, Yi KW, et al. Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reprod Sci. 2018; 25 (10): 1515–22. DOI: 10.1177/1933719118779733
47. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017; 211: 108–11. DOI: 10.1016/j.ejogrb.2017.02.015
48. Barra F, Scala C, Maggiore ULR, Ferrero S. Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis. J Clin Med. 2020; 9 (1): 154. DOI: 10.3390/jcm9010154
DOI: 10.1038/s41574-019-0245-z
2. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017; 6 (1): 34–41. DOI: 10.1007/s13669-017-0187-1
3. Ghiasi M, Kulkarni MT, Missmer SA. Is Endometriosis More Common and More Severe Than It Was 30 Years Ago? J Minim Invasive Gynecol. 2020; 27 (2): 452–61. DOI: 10.1016/j.jmig.2019.11.018
4. Матвеева Н.Н., Табачкова О.А. Структура доброкачественных новообразований яичников у женщин репродуктивного возраста. Бюл. мед. интернет-конференций. 2016; 6 (2): 424 [Matveeva NN, Tabachkova OA. Struktura dobrokachestvennykh novoobrazovanii iaichnikov u zhenshchin reproduktivnogo vozrasta. Biul. med. internet-konferentsii. 2016; 6 (2): 424 (in Russian)].
5. Cranney R, Condous G, Reid S. An update on the diagnosis, surgical management, and fertility outcomes for women with endometrioma. Acta Obstet Gynecol Scand. 2017; 96 (6): 633–43. DOI: 10.1111/aogs.13114
6. Alborzi S, Sorouri ZZ, Askari E, et al. The success of various endometrioma treatments in infertility: A systematic review and meta‐analysis of prospective studies. Reprod Med Biol. 2019; 18 (4): 312–22. DOI: 10.1002/rmb2.12286
7. Miller CE. The Endometrioma Treatment Paradigm when Fertility Is Desired: A Systematic Review. J Minim Invasive Gynecol. 2021; 28 (3): 575–86. DOI: 10.1016/j.jmig.2020.11.020
8. Dunselman G, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29 (3): 400–12. DOI: 10.1093/humrep/det457
9. Дублинская Е.Д., Дутов А.А., Лаптева Н.В., и др. Эндометриоидные кисты яичников и фертильность: дискуссионные аспекты. Вопр. гинекологии, акушерства и перинатологии. 2015; 14 (5): 27–35 [Dublinskaia ED, Dutov AA, Lapteva NV, et al. Endometrioidnye kisty iaichnikov i fertil’nost’: diskussionnye aspekty. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (5): 27–35 (in Russian)].
10. Li X, Zhang W, Chao X, et al. Clinical characteristics difference between early and late recurrence of ovarian endometriosis after laparoscopic cystectomy. Arch Gynecol Obstet. 2020; 302: 905–13. DOI: 10.1007/s00404-020-05657-5
11. Seo JW, Lee DY, Yoon BK, et al. The age-related recurrence of endometrioma after conservative surgery. Eur J Obstet Gynecol Reprod Biol. 2017; 208: 81–5. DOI: 10.1016/j.ejogrb.2016.11.015
12. Kitajima M, Defrere S, Dolmans MM, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011; 96: 685–91. DOI: 10.1016/j.fertnstert.2011.06.064
13. Sanchez AM, Vigano P, Somigliana E, et al. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma‐mediated damage to the ovary. Hum Reprod Update. 2014; 20 (2): 217–30. DOI: 10.1093/humupd/dmt053
14. Sanchez AM, Vanni VS, Bartiromo L, et al. Is the oocyte quality affected by endometriosis? A review of the literature. J Ovarian Res. 2017; 10: 43. DOI: 10.1186/s13048-017-0341-4
15. Matsuzaki S, Schubert B. Oxidative stress status in normal ovarian cortex surrounding ovarian endometriosis. Fertil Steril. 2010; 93 (7): 2431–2. DOI: j.fertnstert.2009.08.068
16. Li Y, Li R, Ouyang N, et al. Investigating the impact of local inflammation on granulosa cells and follicular development in women with ovarian endometriosis. Fertil Steril. 2019; 112: 882–91. DOI: 10.1016/j.fertnstert.2019.07.007
17. Yland J, Carvalho LFP, Beste M, et al. Endometrioma, the follicular fluid inflammatory network and its association with oocyte and embryo characteristics. Reprod Biomed Online. 2020; 40 (3): 399–408. DOI: 10.1016/j.rbmo.2019.12.005
18. Muzii L, Di Tucci C, Di Feliciantonio M, et al. Anti-mullerian hormone is reduced in the presence of ovarian endometriomas: a systematic review and meta-analysis. Fertil Steril. 2018; 110: 932–40. DOI: 10.1016/j.fertnstert.2018.06.025
19. Stochino-Loi E, Darwish B, Mircea O, et al. Does preoperative antimüllerian hormone level influence postoperative pregnancy rate in women undergoing surgery for severe endometriosis? Fertil Steril. 2017; 107: 707–13. DOI: 10.1016/j.fertnstert.2016.12.013
20. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum Reprod Update. 2015; 21: 809–25. DOI: 10.1093/humupd/dmv035
21. Benaglia L, Castiglioni M, Paffoni A, et al. Is endometrioma-associated damage to ovarian reserve progressive? Insights from IVF cycles. Eur J Obstet Gynecol Reprod Biol. 2017; 217: 101–5. DOI: 10.1016/j.ejogrb.2017.08.034
22. Kasapoglu I, Ata B, Uyaniklar O, et al. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018; 110: 122–7. DOI: 10.1016/j.fertnstert.2018.03.015
23. Ding D, Wang X, Chen Y, et al. Evidence in Support for the Progressive Nature of Ovarian Endometriomas. J Clin Endocrinol Metab. 2020; 105 (7): dgaa189. DOI: 10.1210/clinem/dgaa189
24. Kusunoki M, Fujiwara Y, Komohara Y, et al. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. Med Mol Morphol. 2021 Jan 4. Online ahead of print. DOI: 10.1007/s00795-020-00272-4
25. Адамян Л.В. Диагностика и лечение доброкачественнных новообразований яичников с позиций профилактики рака. Клинические рекомендации Минздрава России. М., 2018; с. 20–31 [Adamyan LV. Diagnostics and treatment of benign ovarian neoplasms from the standpoint of cancer prevention. Clinical guidelines of the Ministry of Health of Russia. Moscow, 2018; р. 20–31 (in Russian)].
26. Working group of ESGE, ESHRE and WES; Saridogan E, Becker CM, Feki A, et al. Recommendations for the Surgical Treatment of Endometriosis. Part 1: Ovarian Endometrioma. Human Reprod Open 2017; 4. DOI: 10.1093/hropen/hox016
27. Singh SS, Gude K, Perdeaux E, et al. Surgical Outcomes in Patients With Endometriosis: A Systematic Review. J Obstet Gynaecol Can. 2020; 7: 881–8. DOI: 10.1016/j.jogc.2019.08.004
28. Lessey BA, Gordts S, Donnez O, et al. Ovarian endometriosis and infertility: in vitro fertilization (IVF) or surgery as the first approach? Fertil Steril. 2018; 110 (7): 1218–26. DOI: 10.1016/j.fertnstert.2018.10.003
29. Shaltout MF, Elsheikhah A, Maged AM, et al. A randomized controlled trial of a new technique for laparoscopic management of ovarian endometriosis preventing recurrence and keeping ovarian reserve. J Ovarian Res. 2019; 12 (1): 66. DOI: 10.1186/s13048-019-0542-0
30. Nirgianakis K, Ma L, McKinnon B, Mueller MD. Recurrence Patterns after Surgery in Patients with Different Endometriosis Subtypes:
A Long-Term Hospital-Based Cohort Study. J Clin Med. 2020; 9 (2): 496. DOI: 10.3390/jcm9020496
31. Romualdi D, Zannoni GF, Lanzoneet A, et al. Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations. Fertil Steril. 2011; 96: 374–8. DOI: 10.1016/j.fertnstert.2011.05.078
32. Zakhari A, Delpero E, McKeown S, et al. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2021; 27 (1): 96–107. DOI: 10.1093/humupd/dmaa033
33. Vercellini P, De Matteis S, Somigliana E, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2013; 92: 8–16. DOI: 10.1111/j.1600-0412.2012.01470.x
34. Chapron C, Souza C, Borghese B, et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod. 2011; 26 (8): 2028–35. DOI: 10.1093/humrep/der156
35. Kwok H, Jiang H, Li T, et al. Lesion distribution characteristics of deep infiltrating endometriosis with ovarian endometrioma: an observational clinical study. BMC Women’s Health. 2020; 20: 111. DOI: 10.1186/s12905-020-00974-y
36. Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020; 26 (4): 565–85. DOI: 10.1093/humupd/dmaa009
37. Murji A, Biberoğlu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36 (5): 895–907. DOI: 10.1080/03007995.2020.1744120
38. Park SY, Kim SH, Chae HD, et al. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months. Clin Exp Reprod Med. 2016; 43: 215–20. DOI: 10.5653/cerm.2016.43.4.215
39. Adachi K, Takahashi K, Nakamura K, et al. Postoperative Administration of Dienogest for Suppressing Recurrence of Disease and Relieving Pain in Subjects With Ovarian Endometriomas. Gynecol Endocrinol. 2016; 32 (8): 646–9. DOI: 10.3109/09513590.2016.1147547
40. Chandra A, Rho AM, Jeonget K, et al. Clinical Experience of Long-Term Use of Dienogest After Surgery for Ovarian Endometrioma. Obstet Gynecol Sci. 2018; 61 (1): 111–7. DOI: 10.5468/ogs.2018.61.1.111
41. Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020; 36 (1): 84–6. DOI: 10.1080/09513590.2019.1640674
42. Mabrouk M, Paradisi R, Arena A, et al. Short-term histopathological effects of dienogest therapy on ovarian endometriomas: in vivo, nonrandomized, controlled trial. Gynecol Endocrinol. 2018; 34 (5): 399–403. DOI: 10.1080/09513590.2017.1405932
43. Hayashi A, Tanabe A, Kawabe S, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovar Res. 2012; 5: 31–9. DOI: 10.1186/1757-2215-5-31
44. Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020; 36 (1): 81–8. DOI: 10.1080/09513590.2019.1640199
45. Koshiba A, Mori T, Okimura H, et al. Dienogest Therapy During the Early Stages of Recurrence of Endometrioma Might Be an Alternative Therapeutic Option to Avoid Repeat Surgeries. J Obstet Gynaecol Res. 2018; 44 (7): 1189–341. DOI: 10.1111/jog.13725
46. Lee JH, Song JY, Yi KW, et al. Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reprod Sci. 2018; 25 (10): 1515–22. DOI: 10.1177/1933719118779733
47. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017; 211: 108–11. DOI: 10.1016/j.ejogrb.2017.02.015
48. Barra F, Scala C, Maggiore ULR, Ferrero S. Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis. J Clin Med. 2020; 9 (1): 154. DOI: 10.3390/jcm9010154
________________________________________________
DOI: 10.1038/s41574-019-0245-z
2. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017; 6 (1): 34–41. DOI: 10.1007/s13669-017-0187-1
3. Ghiasi M, Kulkarni MT, Missmer SA. Is Endometriosis More Common and More Severe Than It Was 30 Years Ago? J Minim Invasive Gynecol. 2020; 27 (2): 452–61. DOI: 10.1016/j.jmig.2019.11.018
4. Matveeva NN, Tabachkova OA. Struktura dobrokachestvennykh novoobrazovanii iaichnikov u zhenshchin reproduktivnogo vozrasta. Biul. med. internet-konferentsii. 2016; 6 (2): 424 (in Russian)
5. Cranney R, Condous G, Reid S. An update on the diagnosis, surgical management, and fertility outcomes for women with endometrioma. Acta Obstet Gynecol Scand. 2017; 96 (6): 633–43. DOI: 10.1111/aogs.13114
6. Alborzi S, Sorouri ZZ, Askari E, et al. The success of various endometrioma treatments in infertility: A systematic review and meta‐analysis of prospective studies. Reprod Med Biol. 2019; 18 (4): 312–22. DOI: 10.1002/rmb2.12286
7. Miller CE. The Endometrioma Treatment Paradigm when Fertility Is Desired: A Systematic Review. J Minim Invasive Gynecol. 2021; 28 (3): 575–86. DOI: 10.1016/j.jmig.2020.11.020
8. Dunselman G, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29 (3): 400–12. DOI: 10.1093/humrep/det457
9. Dublinskaia ED, Dutov AA, Lapteva NV, et al. Endometrioidnye kisty iaichnikov i fertil’nost’: diskussionnye aspekty. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (5): 27–35 (in Russian)
10. Li X, Zhang W, Chao X, et al. Clinical characteristics difference between early and late recurrence of ovarian endometriosis after laparoscopic cystectomy. Arch Gynecol Obstet. 2020; 302: 905–13. DOI: 10.1007/s00404-020-05657-5
11. Seo JW, Lee DY, Yoon BK, et al. The age-related recurrence of endometrioma after conservative surgery. Eur J Obstet Gynecol Reprod Biol. 2017; 208: 81–5. DOI: 10.1016/j.ejogrb.2016.11.015
12. Kitajima M, Defrere S, Dolmans MM, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011; 96: 685–91. DOI: 10.1016/j.fertnstert.2011.06.064
13. Sanchez AM, Vigano P, Somigliana E, et al. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma‐mediated damage to the ovary. Hum Reprod Update. 2014; 20 (2): 217–30. DOI: 10.1093/humupd/dmt053
14. Sanchez AM, Vanni VS, Bartiromo L, et al. Is the oocyte quality affected by endometriosis? A review of the literature. J Ovarian Res. 2017; 10: 43. DOI: 10.1186/s13048-017-0341-4
15. Matsuzaki S, Schubert B. Oxidative stress status in normal ovarian cortex surrounding ovarian endometriosis. Fertil Steril. 2010; 93 (7): 2431–2. DOI: j.fertnstert.2009.08.068
16. Li Y, Li R, Ouyang N, et al. Investigating the impact of local inflammation on granulosa cells and follicular development in women with ovarian endometriosis. Fertil Steril. 2019; 112: 882–91. DOI: 10.1016/j.fertnstert.2019.07.007
17. Yland J, Carvalho LFP, Beste M, et al. Endometrioma, the follicular fluid inflammatory network and its association with oocyte and embryo characteristics. Reprod Biomed Online. 2020; 40 (3): 399–408. DOI: 10.1016/j.rbmo.2019.12.005
18. Muzii L, Di Tucci C, Di Feliciantonio M, et al. Anti-mullerian hormone is reduced in the presence of ovarian endometriomas: a systematic review and meta-analysis. Fertil Steril. 2018; 110: 932–40. DOI: 10.1016/j.fertnstert.2018.06.025
19. Stochino-Loi E, Darwish B, Mircea O, et al. Does preoperative antimüllerian hormone level influence postoperative pregnancy rate in women undergoing surgery for severe endometriosis? Fertil Steril. 2017; 107: 707–13. DOI: 10.1016/j.fertnstert.2016.12.013
20. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum Reprod Update. 2015; 21: 809–25. DOI: 10.1093/humupd/dmv035
21. Benaglia L, Castiglioni M, Paffoni A, et al. Is endometrioma-associated damage to ovarian reserve progressive? Insights from IVF cycles. Eur J Obstet Gynecol Reprod Biol. 2017; 217: 101–5. DOI: 10.1016/j.ejogrb.2017.08.034
22. Kasapoglu I, Ata B, Uyaniklar O, et al. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018; 110: 122–7. DOI: 10.1016/j.fertnstert.2018.03.015
23. Ding D, Wang X, Chen Y, et al. Evidence in Support for the Progressive Nature of Ovarian Endometriomas. J Clin Endocrinol Metab. 2020; 105 (7): dgaa189. DOI: 10.1210/clinem/dgaa189
24. Kusunoki M, Fujiwara Y, Komohara Y, et al. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. Med Mol Morphol. 2021 Jan 4. Online ahead of print. DOI: 10.1007/s00795-020-00272-4
25. Adamyan LV. Diagnostics and treatment of benign ovarian neoplasms from the standpoint of cancer prevention. Clinical guidelines of the Ministry of Health of Russia. Moscow, 2018; р. 20–31 (in Russian)
26. Working group of ESGE, ESHRE and WES; Saridogan E, Becker CM, Feki A, et al. Recommendations for the Surgical Treatment of Endometriosis. Part 1: Ovarian Endometrioma. Human Reprod Open 2017; 4. DOI: 10.1093/hropen/hox016
27. Singh SS, Gude K, Perdeaux E, et al. Surgical Outcomes in Patients With Endometriosis: A Systematic Review. J Obstet Gynaecol Can. 2020; 7: 881–8. DOI: 10.1016/j.jogc.2019.08.004
28. Lessey BA, Gordts S, Donnez O, et al. Ovarian endometriosis and infertility: in vitro fertilization (IVF) or surgery as the first approach? Fertil Steril. 2018; 110 (7): 1218–26. DOI: 10.1016/j.fertnstert.2018.10.003
29. Shaltout MF, Elsheikhah A, Maged AM, et al. A randomized controlled trial of a new technique for laparoscopic management of ovarian endometriosis preventing recurrence and keeping ovarian reserve. J Ovarian Res. 2019; 12 (1): 66. DOI: 10.1186/s13048-019-0542-0
30. Nirgianakis K, Ma L, McKinnon B, Mueller MD. Recurrence Patterns after Surgery in Patients with Different Endometriosis Subtypes:
A Long-Term Hospital-Based Cohort Study. J Clin Med. 2020; 9 (2): 496. DOI: 10.3390/jcm9020496
31. Romualdi D, Zannoni GF, Lanzoneet A, et al. Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations. Fertil Steril. 2011; 96: 374–8. DOI: 10.1016/j.fertnstert.2011.05.078
32. Zakhari A, Delpero E, McKeown S, et al. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2021; 27 (1): 96–107. DOI: 10.1093/humupd/dmaa033
33. Vercellini P, De Matteis S, Somigliana E, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2013; 92: 8–16. DOI: 10.1111/j.1600-0412.2012.01470.x
34. Chapron C, Souza C, Borghese B, et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod. 2011; 26 (8): 2028–35. DOI: 10.1093/humrep/der156
35. Kwok H, Jiang H, Li T, et al. Lesion distribution characteristics of deep infiltrating endometriosis with ovarian endometrioma: an observational clinical study. BMC Women’s Health. 2020; 20: 111. DOI: 10.1186/s12905-020-00974-y
36. Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020; 26 (4): 565–85. DOI: 10.1093/humupd/dmaa009
37. Murji A, Biberoğlu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36 (5): 895–907. DOI: 10.1080/03007995.2020.1744120
38. Park SY, Kim SH, Chae HD, et al. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months. Clin Exp Reprod Med. 2016; 43: 215–20. DOI: 10.5653/cerm.2016.43.4.215
39. Adachi K, Takahashi K, Nakamura K, et al. Postoperative Administration of Dienogest for Suppressing Recurrence of Disease and Relieving Pain in Subjects With Ovarian Endometriomas. Gynecol Endocrinol. 2016; 32 (8): 646–9. DOI: 10.3109/09513590.2016.1147547
40. Chandra A, Rho AM, Jeonget K, et al. Clinical Experience of Long-Term Use of Dienogest After Surgery for Ovarian Endometrioma. Obstet Gynecol Sci. 2018; 61 (1): 111–7. DOI: 10.5468/ogs.2018.61.1.111
41. Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020; 36 (1): 84–6. DOI: 10.1080/09513590.2019.1640674
42. Mabrouk M, Paradisi R, Arena A, et al. Short-term histopathological effects of dienogest therapy on ovarian endometriomas: in vivo, nonrandomized, controlled trial. Gynecol Endocrinol. 2018; 34 (5): 399–403. DOI: 10.1080/09513590.2017.1405932
43. Hayashi A, Tanabe A, Kawabe S, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovar Res. 2012; 5: 31–9. DOI: 10.1186/1757-2215-5-31
44. Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020; 36 (1): 81–8. DOI: 10.1080/09513590.2019.1640199
45. Koshiba A, Mori T, Okimura H, et al. Dienogest Therapy During the Early Stages of Recurrence of Endometrioma Might Be an Alternative Therapeutic Option to Avoid Repeat Surgeries. J Obstet Gynaecol Res. 2018; 44 (7): 1189–341. DOI: 10.1111/jog.13725
46. Lee JH, Song JY, Yi KW, et al. Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reprod Sci. 2018; 25 (10): 1515–22. DOI: 10.1177/1933719118779733
47. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017; 211: 108–11. DOI: 10.1016/j.ejogrb.2017.02.015
48. Barra F, Scala C, Maggiore ULR, Ferrero S. Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis. J Clin Med. 2020; 9 (1): 154. DOI: 10.3390/jcm9010154
Авторы
Г.Е. Чернуха*1, М.Р. Думановская1, Л.М. Ильина2
1 ФГБУ «Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия;
2 Ассоциация гинекологов-эндокринологов, Москва, Россия
*g_chernukha@oparina4.ru
1 Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia;
2 Association of Gynecologists-Endocrinologists, Moscow, Russia
*g_chernukha@oparina4.ru
1 ФГБУ «Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия;
2 Ассоциация гинекологов-эндокринологов, Москва, Россия
*g_chernukha@oparina4.ru
________________________________________________
1 Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia;
2 Association of Gynecologists-Endocrinologists, Moscow, Russia
*g_chernukha@oparina4.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.